UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-41097 Cardio Diagnostics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 87-0925574 (St ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to _____________ Commission File Number: 001-41612 ASSET ENTITIES INC. (Exact name of registrant as specified in its charter) Nevada 88-1293236 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 1847 Holdings LLC | (Exact name of registrant as specified in its charter) | | | | --- | --- | --- | | Delaware | 001-41368 | 38-3922937 | | (State or other jurisdiction | (Commission File Number) | (IRS Employer | | of incorporation) | | Identification No.) | | 260 Madison Avenue, ...

Exhibit 99.1 Lakeside Announces Fiscal 2025 Third Quarter and Nine-Month Results ITASCA, IL, May 15, 2025 (GLOBE NEWSWIRE) -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market operating through two specialized subsidiaries—American Bear Logistics and Hupan Pharmaceutical (Hubei) Co., Ltd., today announced financial results for its fiscal 2025 third quarter and nine months ended March 3 ...

Financial Results and Updates - TuHURA Biosciences reported financial results for Q1 2025, with a focus on corporate updates[7]. - TuHURA's financial condition and operational results are detailed in the press release dated May 15, 2025[7]. - The company has not undertaken any obligation to update forward-looking statements unless required by securities laws[14]. Acquisition and Merger - The company is in the process of acquiring Kineta, Inc., with a registration statement filed on February 7, 2025[8]. - The merger with Kineta is expected to enhance TuHURA's capabilities in tumor microenvironment modulators[13]. - TuHURA is actively seeking additional capital to support the Kineta merger and its ongoing development programs[13]. - The company emphasizes the importance of reading the Joint Proxy Statement/Prospectus for detailed information regarding the merger[9]. Product Development - TuHURA's product candidate IFx-Hu2.0 is anticipated to enter Phase 3 trials, indicating progress in its development pipeline[13]. - The anticipated regulatory pathway and timing for TuHURA's development programs are outlined as part of their forward-looking statements[13]. Stock Information - TuHURA's stock is traded on The Nasdaq Capital Market under the symbol HURA[5].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Nevada 001-37823 99-0360497 (Commission File Number) (IRS Employer (State or Other Jurisdiction of Incorporation) Identification No.) FORM 8-K 10500 University Center Dr., Suite 110 Tampa, Florida 33612 (Address of Principal Executive Offices, including zip code) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Registrant's Telephone Number, Including Area Code: (813) 875-6600 Date of Report (Date of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | SLAM CORP. | | --- | (Exact name of registrant as specified in its charter) | Cayman Islands | 001-40094 | 98-1211848 | | --- | --- | --- | | (State or other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to _________ 001-39732 Commission File Number Alset Inc. (Exact name of registrant as specified in its charter) TEXAS 83-1079861 State or other jurisdiction of ...

Revenue Performance - Revenue for Q4 2024 was $73.3 million, a 1.1% increase from $72.5 million in Q4 2023, driven by a $1.1 million growth in IoT Connectivity revenue[5] - Full year revenue totaled $286.1 million, up $9.5 million or 3.4% from $276.6 million in 2023, with IoT Connectivity revenue increasing by $24.5 million to $226.9 million[9] - KORE's total revenue for the year ended December 31, 2024, was $146,076,000, down from $167,042,000 in 2023[38] - The company expects revenue for 2025 to be in the range of $288 million to $298 million[14] Financial Loss and Improvement - Net loss for Q4 2024 improved to $25.4 million, a reduction of 24.6% compared to $33.7 million in Q4 2023[9] - KORE Group Holdings reported a net loss of $25,448,000 for Q4 2024, an improvement from a net loss of $33,692,000 in Q4 2023[38] - The company incurred a goodwill impairment loss of $65,861,000 for the year ended December 31, 2024[38] Cash Flow and EBITDA - Adjusted EBITDA for Q4 2024 was $14.0 million, a slight increase of 1.1% from $13.8 million in Q4 2023[9] - Adjusted EBITDA for Q4 2024 was $13,976,000, slightly up from $13,824,000 in Q4 2023[38] - Free Cash Flow for Q4 2024 was $1.6 million, a significant improvement from a negative $15.5 million in Q4 2023[9] - Free cash flow for Q4 2024 was $1,562,000, compared to a negative free cash flow of $15,546,000 in Q4 2023[39] - Total cash provided by operating activities for Q4 2024 was $2,840,000, a significant recovery from a cash used of $10,912,000 in Q4 2023[39] Operational Metrics - The total number of IoT Connections increased by 1.2 million to 19.7 million by the end of 2024[4] - The Dollar-Based Net Expansion Rate (DBNER) for the twelve months ending December 31, 2024, was 95%, down from 96% in the previous year[11] - KORE's average revenue per user (ARPU) is a key metric for assessing revenue generation per connection, calculated on a quarterly basis[33][34] Restructuring and Future Outlook - KORE completed its restructuring plan, resulting in over $20 million in annual run-rate savings[5] - Notable new business wins in Q4 included closed-won Total Contract Value (TCV) of $29.3 million, with $9.4 million related to Connectivity[13] - The company anticipates future revenue growth and operational efficiency improvements as part of its restructuring plan[35] - KORE's integration-related restructuring costs for the year were $19,159,000, compared to $16,532,000 in 2023[38] - The company reported a change in fair value of warrant liability of $2,309,000 for Q4 2024[38]

Table of Contents (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-36333 Bio-Path Holdings, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ...